Repligen Corporation Profile Avatar - Palmy Investing

Repligen Corporation

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding com…

Medical - Instruments & Supplies
US, Waltham [HQ]
RGEN/Financial Reporting

Income Statements

14 Sheets · Starting from 2010
In Million USD. Margins, Growth Rates In %
Metric 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Revenue
20.00 27.00 62.00 68.00 63.00 83.00 104.00 141.00 194.00 270.00 366.00 670.00 801.00 638.00
EPS
-0.13 - - 0.46 0.51 0.25 0.28 0.35 0.74 0.38 0.44 1.14 2.33 3.35 0.75
Profit
15.00 20.00 35.00 43.00 35.00 48.00 57.00 74.00 108.00 151.00 209.00 391.00 455.00 284.00
Pre Tax
-4.00 - - 11.00 23.00 11.00 13.00 11.00 7.00 21.00 26.00 59.00 153.00 219.00 64.00
ETR
17.04 759.76 -25.59 30.07 26.65 30.38 0.09 -291.18 22.48 18.13 -1.20 16.45 15.14 35.17
Net
-4.00 - - 14.00 16.00 8.00 9.00 11.00 28.00 16.00 21.00 59.00 128.00 185.00 41.00
EBITDA
-4.00 1.00 11.00 22.00 12.00 17.00 18.00 13.00 26.00 35.00 69.00 171.00 184.00 131.00
Operating Income
-5.00 - - 11.00 22.00 10.00 13.00 15.00 14.00 25.00 14.00 42.00 133.00 133.00 63.00
Interest Income
- - - - - - - - - - - - - - - - - - 5.00 1.00 - - 6.00 24.00
Loss
-26.00 -27.00 -50.00 -45.00 -50.00 -65.00 -85.00 -127.00 -168.00 -234.00 -296.00 -497.00 -605.00 -575.00
Cost of Revenue
-5.00 -7.00 -27.00 -25.00 -28.00 -35.00 -47.00 -67.00 -85.00 -119.00 -156.00 -279.00 -345.00 -354.00
Operating Expenses
-21.00 -20.00 -23.00 -20.00 -22.00 -30.00 -38.00 -60.00 -82.00 -115.00 -139.00 -218.00 -259.00 -220.00
Depreciation and Amortization
-1.00 -1.00 -3.00 -3.00 -4.00 -4.00 -5.00 -10.00 -15.00 -20.00 -27.00 -38.00 -50.00 -68.00
Interest Expenses
- - - - - - - - - - - - -3.00 -6.00 -6.00 -9.00 -12.00 -12.00 -1.00 -10.00
Other Expenses
- - - - - - - - -1.00 -4.00 -3.00 - - -2.00 -11.00 -16.00 -20.00 -85.00 - -
WA Shares Outstanding
30.00 30.00 30.00 31.00 32.00 32.00 33.00 38.00 43.00 48.00 52.00 55.00 55.00 55.00
End of RGEN's Analysis
CIK: 730272 CUSIP: 759916109 ISIN: US7599161095 LEI: - UEI: -
Secondary Listings
RGEN has no secondary listings inside our databases.